Given the propensity for ALK rearranged NSCLC to develop central nervous system (CNS) metastases, and the activity of bevacizumab for radiation necrosis [97], this may be a specific subset of patients that may benefit from bevacizumab therapy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.